Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
The MEIP news page on Stock Titan provides an organized view of public announcements and regulatory disclosures related to MEI Pharma, Inc. and its transition to Lite Strategy, Inc. These items trace the company’s path from a clinical-stage oncology business with a portfolio of cancer drug candidates to an enterprise emphasizing a Litecoin-focused digital asset treasury strategy.
Earlier news releases describe MEI Pharma’s work as a pharmaceutical company with drug candidates such as voruciclib and ME-344, along with updates on cash position, research and development spending, and the evaluation of strategic alternatives. These reports document the company’s efforts to preserve cash, consider out-licensing and merger and acquisition options, and adjust its workforce and clinical programs while seeking to maximize asset value for stockholders.
More recent articles highlight a major strategic shift: the launch of a Litecoin treasury initiative, a large private placement to fund this strategy, and the acquisition of a substantial Litecoin position. The company’s news also details the appointment of digital asset advisors, board changes linked to its treasury focus, and the formal rebranding to Lite Strategy, Inc. with a new NASDAQ ticker symbol, LITS.
Investors and researchers using this page can follow how MEI Pharma’s oncology-focused narrative evolved into a digital asset treasury story, including key milestones such as the private placement, Litecoin acquisitions, and the corporate name and ticker change. For ongoing developments after the symbol transition, users should also review news associated with Lite Strategy, Inc. under its current trading symbol.
MEI Pharma, a clinical-stage pharmaceutical company, reported positive results for the third quarter fiscal year 2024, highlighting promising clinical data for voruciclib and ME-344. The ongoing Phase 1 study evaluating voruciclib plus venetoclax in R/R AML patients showed anti-leukemic activity, with complete responses and significant decreases in Mcl-1 levels. MEI's Board of Directors is focused on advancing the voruciclib program, with a cash balance of $56.6 million. MEI also initiated research on a new ME-344 formulation and decided to prioritize clinical development of voruciclib. Financially, MEI had no debt, $56.6 million in cash, and believes its cash balance is sufficient for the next 12 months.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Mei Pharma (MEIP)?
What is the market cap of Mei Pharma (MEIP)?
